R1 kicks off with $77.5 million for a chronic kidney disease drug

R1 Therapeutics’ new biotechnology comes with fresh support and a new condition to facilitate the treatment of long-term kidney problems. Biotech funding rounds can sometimes overlap: a new company starts up, investors pile in, a promising molecule gets another shot…












